Scopus BioPharma Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 15.282 million compared to USD 7.945 million a year ago. Net loss was USD 15.628 million compared to USD 8.025 million a year ago. Basic loss per share from continuing operations was USD 0.97 compared to USD 0.62 a year ago. For the half year, operating loss was USD 18.355 million compared to USD 8.564 million a year ago. Net loss was USD 19.034 million compared to USD 8.651 million a year ago. Basic loss per share from continuing operations was USD 1.21 compared to USD 0.68 a year ago.